Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

ACCREDITED SYMPOSIA

203 - ADVANCES IN PULMONARY HYPERTENSION – ENHANCING CARE THROUGH INNOVATION AND COLLABORATION

Friday, October 25, 2024
12:30 PM – 1:30 PM PT
Room: 109-110
On-Demand
Join us for an accredited symposium focused on pulmonary hypertension (PH), designed for a diverse audience including general practitioners, specialists, and allied healthcare providers. This 1-hour symposium will feature four presentations and a Q&A session, aiming to enhance participants’ ability to integrate evidence-based strategies for PH diagnosis, referral, and management. Presenters will discuss the importance of a patient-centred, multidisciplinary management approach and specialized PH clinics. Key topics will include the referral process to PH centres and recent advances in PH management, such as new echocardiography guidelines and emerging therapies. The experts will also explore the roles of various healthcare professionals in a PH care team and the impact of recent developments on patient outcomes and quality of life. The symposium will include a presentation from a patient who will share their lived experiences, from symptoms to specialist care.

Learning Objectives:

At the end of this session participants will be able to:
  • Integrate current evidence-based strategies for the diagnosis, referral, and management of pulmonary hypertension in clinical practice;
  • Implement a patient-centered, multidisciplinary approach to pulmonary hypertension care, highlighting the role of specialized PH clinics; and
  • Evaluate recent advances in pulmonary hypertension management and their potential impact on patient outcomes and quality of life
Disclosure(s):
Lisa Mielniczuk, BSc, MSc, MD, FRCPC: Astra Zeneca: Ad Boards (Ongoing), speaker fees (Ongoing); GSK: ad boards (Ongoing), speaker fees (Ongoing); Janssen: ad boards (Ongoing), speaker fees (Ongoing); Merck: ad boards (Ongoing); Servier: speaker fees (Terminated, January 1, 2023)
Sharon L. Mulvagh, MD, FRCPC: Novo Nordisk: Steering Committee for SOUL Clinical Trial (Ongoing)